AstraZeneca and Amgen reported positive phase 3 results for tezepelumab (Tezspire) in eosinophilic esophagitis (EoE), with coprimary endpoints and key secondary endpoints met in the Crossing trial. The outcome, if it translates into an eventual filing and label update, would position Tezspire for a third indication beyond asthma and chronic rhinosinusitis with nasal polyps. The EoE space is already crowded clinically, but approved biologic options remain limited; Tezspire’s success would strengthen competition against the current standard biologic landscape. Commercial analysts will likely focus on the durability of effect, patient selection strategies, and how Tezspire’s safety profile integrates with long-term management of chronic EoE. The phase 3 win also keeps AstraZeneca’s and Amgen’s immune-inflammation pipeline progression on track as they work through regulatory steps after a late-stage efficacy signal.